Quarterly Result5 Feb 2026, 01:50 pm
Anthem Biosciences Reports ¥15,134 Mn Revenue in IMFY26 with 24.8% PAT Margins
AI Summary
Anthem Biosciences Limited, a CRDMO, announced its unaudited results for the third quarter and period ended December 31, 2025. The company reported a consolidated revenue from operations of ¥15,134 Mn for IMFY26, with a profit after tax (PAT) of ¥34,020 Mn, representing a PAT margin of 24.8%. The CRDMO business delivered ¥12,599 Mn revenues, while the Specialty Ingredients contributed ¥2,535 Mn. The EBITDA stood at ¥6,712 Mn with a margin of 41.5%. The net cash position as of Dec 31, 2025, is ¥12,312 Mn. The company has made a provision of ¥254 Mn as an Exceptional Item due to the new Labour Codes in India.
Key Highlights
- Consolidated Revenue from Operations for IMFY26 was ¥15,134 Mn
- PAT at ¥34,020 Mn, with PAT margins at 24.8%
- CRDMO business delivered ¥12,599 Mn revenues
- Specialty Ingredients delivered ¥2,535 Mn revenues
- EBITDA was ¥6,712 Mn, with EBITDA margins at 41.5%